GOLDEN, Colo. — April 24, 2024 — PharmaJet®, a company that strives to improve the performance and outcomes of medicines with its innovative delivery systems, today announced the Nature publication of Gennova Biopharmaceutical’s Phase 2/3 clinical trial conducted to evaluate the safety and immunogenicity of its novel samRNA-based Covid-19 vaccine
View GOLDEN, Colo. — June 28, 2023 – PharmaJet®, a company engineering precision delivery systems that overcome challenges of nucleic acid vaccine delivery, today announced that its Tropis® System is now the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines:
View GOLDEN, Colo. — April 4, 2023 — Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET.
View GOLDEN, Colo. — April 3, 2023 – Following completion of Phase II/III study, PharmaJet partner Gennova Biopharmaceuticals Limited has submitted data for its mRNA-based Omicron specific Covid-19 booster shot for Emergency Use Authorization (EUA) to the office of the drug controller General of India (DCGI). The submission corresponds with an
View GOLDEN, Colo. — March 21, 2023 — PharmaJet®, a company engineering precision delivery systems that may overcome the challenges of nucleic acid vaccine delivery, today announced that its partner, Scancell, a developer of novel immunotherapies for the treatment of cancer and infectious diseases, reported positive results from their Phase 1
View GOLDEN, Colo. — February 23, 2023 — In a review article recently published in Vaccines Journal (MDPI), Dr. Carmen Ledesma-Feliciano, Scientific Affairs Manager at PharmaJet, referencing over 25 studies, discusses multiple injection delivery methods including PharmaJet’s needle-free precision delivery systems, which enhance the clinical performance of DNA-based vaccines.
View GOLDEN, Colo. — September 27, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their latest research results will be presented at five upcoming conferences in October:
View GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection
View PharmaJet presents latest research showing Benefits of Needle-free at mRNA-Based Therapeutics Summit
GOLDEN, Colo. — July 19, 2022 — PharmaJet® , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022. The presentation, entitled Advances in
View Load more